Pancreatic Cancer Market Research Report- Global Forecast till 2023

Penetrating Cancer Market Information: By Type (Endocrine Pancreas Cancer and Exocrine Pancreas Cancer), Treatment (Hormone Therapy, Biologic Therapy, and Targeted Therapy), End User (Hospitals & Clinics and Research Institute) - Global Forecast till 2023

Market Scenario

Endocrine pancreas cancer and exocrine pancreas cancer are two types of pancreatic cancer. These cancerous cells become more malignant when they migrate to the other part of the body through blood. It is one of the least treatable forms of cancer around.

According to the WHO, cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths. Furthermore, pancreatic cancer was the twelfth most common type of cancer in the same year. The factors that cause pancreatic cancer are cigarettes, cigars, pipes and chewing tobacco. According to the study done by Cancer Research U.K, looking at the lifestyle factors found that out of three pancreatic cancer, one may be linked to smoking. Additionally, around seven out of ten cases of chronic pancreatitis are due to long-term heavy consumption of alcohol.

Pancreatic cancer is hard to catch, even if we are aware of the symptoms to search for. This leads to a late diagnosis and makes treatment more difficult. Many treatments for pancreatic cancer are available in the market such as chemotherapy, surgery, radiotherapy, and targeted therapy. Whereas the surgery is considered as a first treatment option for pancreatic cancer, just like any other cancer. Pancreatic cancer is one of the painful cancers, and the survivor gets relief only if they get treatment on early stage. Furthermore, these treatments prolong the lifespan of the patient if treated on time. Thus, the earlier it is detected, the better would be the prognosis.

Moreover, advancing technology in medical devices is adding fuel to the growth of the market. Furthermore, increasing prevalence of cancer drives the market growth. However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors which may hamper the market growth during the forecast period.

The global pancreatic cancer market is expected to grow at a CAGR of 8.1% during the forecast period 2017-2023.

Intended Audience

- Medical Oncologists
- Oncology Nurses
- Medical Companies
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities

Figure: Global Pancreatic cancer Market, By Region Market Share, 2016 (%)

Price

| Price         | 1-user PDF : $ 4450.0 | Enterprise PDF : $ 6250.0 |

Report Information

More information from: https://www.marketresearchfuture.com/reports/1638
Segmentations

The global pancreatic cancer market is segmented on the basis of types, treatment, and end user.

On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others.

On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is sub-segmented into tyrosine kinase inhibitors and monoclonal antibodies. And the hormone therapy is sub-segmented into estrogen-receptor modulators, aromatase inhibitors, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.

Regional Analysis

The Americas dominate the global pancreatic cancer market owing to well-developed technology, increasing patient with cancer, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global pancreatic cancer market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.

Asia Pacific is the fastest growing pancreatic cancer market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe.

On the other hand, in the Middle East and Africa, pancreatic cancer has become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Key Players

Some of key the players in the market are Pharmacyte Biotech Inc. (U.S.), OncoGenex Pharmaceuticals Inc. (U.S.), Oncolytics Biotech (Canada), Diffusion Pharmaceuticals (U.S.), Polaris Pharmaceuticals, Inc. (U.S.), Sun BioPharma, Inc. (U.S.), Midatech Pharma PLC (U.K.), Eli Lilly and Company (U.S.), Celgene Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Amgen, Inc. (U.S.), Novartis International AG (U.S.), Clovis Oncology (U.S.), and others.

Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation

Contents:
Table of Content
1. Report Prologue
2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
   2.2.1 Research Objective
   2.2.2 Assumptions
   2.2.3 Limitations
3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation
4. Market Dynamics
   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Challenges
   4.5 Macroeconomic Indicators
   4.6 Technology Trends & Assessment
5. Market Factor Analysis
   5.1 Porters Five Forces Analysis
      5.1.1 Bargaining Power of Suppliers
      5.1.2 Bargaining Power of Buyers
      5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Pancreatic Cancer Market, by Type
6.1 Introduction
6.2 Endocrine Pancreas Cancer
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Exocrine Pancreas Cancer
6.3.1 Market Estimates & Forecast, 2017-2023
6.4 Others
6.4.1 Market Estimates & Forecast, 2017-2023
7. Global Pancreatic Cancer Market, by Treatment
7.1 Introduction
7.2 Chemotherapy
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Surgery & Radiation Therapy
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Targeted Therapy
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 Biologic Therapy
7.5.1 Market Estimates & Forecast, 2017-2023
7.6 Hormone Therapy
7.6.1 Market Estimates & Forecast, 2017-2023
7.7 Others
7.7.1 Market Estimates & Forecast, 2017-2023
8. Global Pancreatic cancer Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Research institute
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Others
8.4.1 Market Estimates & Forecast, 2017-2023
9. Global Pancreatic cancer Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K.
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 Eli Lilly and Company
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Celgene Corporation
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 F. Hoffmann-La Roche AG
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Amgen, Inc.
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Novartis Ag
11.5.1 Company Overview
Table 26 Eastern Europe Pancreatic cancer Market by Treatment, 2017-2023, (USD Million)
Table 27 Eastern Europe Pancreatic cancer Market by End Users, 2017-2023, (USD Million)
Table 28 Asia Pacific Pancreatic cancer Market by Type, 2017-2023, (USD Million)
Table 29 Asia Pacific Pancreatic cancer Market by Treatment, 2017-2023, (USD Million)
Table 30 Asia Pacific Pancreatic cancer Market by End Users, 2017-2023, (USD Million)
Table 31 Middle East & Africa Pancreatic cancer Market by Type, 2017-2023, (USD Million)
Table 32 Middle East & Africa Pancreatic cancer Market by Treatment, 2017-2023, (USD Million)
Table 33 Middle East & Africa Pancreatic cancer Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Pancreatic cancer Market
Figure 3 Segmentation Market Dynamics for Pancreatic cancer Market
Figure 4 Global Pancreatic cancer Market Share, by Type 2016
Figure 5 Global Pancreatic cancer Market Share, by Treatment 2016
Figure 6 Global Pancreatic cancer Market Share, by End Users, 2016
Figure 7 Global Pancreatic cancer Market Share, by Region, 2016
Figure 8 America Pancreatic cancer Market Share, by Country, 2016
Figure 9 Europe Pancreatic cancer Market Share, by Country, 2016
Figure 10 Asia Pacific Pancreatic cancer Market Share, by Country, 2016
Figure 11 Middle East & Africa Pancreatic cancer Market Share, by Country, 2016
Figure 12 Global Pancreatic cancer Market: Company Share Analysis, 2016 (%)
Figure 13 Eli Lilly and Company: Key Financials
Figure 14 Eli Lilly and Company: Segmental Revenue
Figure 15 Eli Lilly and Company: Geographical Revenue
Figure 16 Celgene Corporation: Key Financials
Figure 17 Celgene Corporation: Segmental Revenue
Figure 18 Celgene Corporation: Geographical Revenue
Figure 19 F. Hoffmann-La Roche AG: Key Financials
Figure 20 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 21 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 22 Amgen, Inc.: Key Financials
Figure 23 Amgen, Inc.: Segmental Revenue
Figure 24 Amgen, Inc.: Geographical Revenue
Figure 25 Novartis AG: Key Financials
Figure 26 Novartis AG: Segmental Revenue
Figure 27 Novartis AG: Geographical Revenue
Figure 28 Pharmacyte Biotech, Inc.: Key Financials
Figure 29 Pharmacyte Biotech, Inc.: Segmental Revenue
Figure 30 Pharmacyte Biotech, Inc.: Geographical Revenue
Figure 31 Clovis Oncology: Key Financials
Figure 32 Clovis Oncology: Segmental Revenue
Figure 33 Clovis Oncology: Geographical Revenue